Central Screening revolutionizes clinical trial enrollment by integrating technology and expertise, streamlining patient matching for targeted cancer therapies.
Andrew McKenzie, PhD
Advertisement
Andrew McKenzie, PhD, is vice president of personalized medicine at the Sarah Cannon Research Institute and scientific director at Genospace in Nashville, Tennessee.
Articles by Andrew McKenzie, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
